Maquet Cardiovascular has gained US and European marketing rights for its new SENSATION PLUS 7.5Fr. 40Cc intra-aortic balloon (IAB) catheter, following the US Food and Drug Administration (FDA) and CE mark approvals respectively.

The new larger-volume IAB catheter is designed for improving hemodynamic support in patients who are 5’0" to 5’4" tall (152-162 cm).

By utilizing the company’s IAB fiber-optic technology, the new catheter displaces more blood in the aorta during diastole, resulting in improved diastolic augmentation and systolic unloading.

MAQUET Cardiovascular president and CEO Christian Keller said the company is committed to develop new products that continuously improve the therapy needs of hemodynamically compromised patients thereby improving patient outcomes.

"Over the last 12 months, MAQUET has launched two new families of IAB catheters, as well as a new balloon pump, CARDIOSAVE – all of which are designed to revolutionize counterpulsation therapy, from both an efficacy and safety perspective," Keller added.

The company said SENSATION PLUS IAB catheters, which come with two STATLOCK IAB stabilization devices, automatically calibrate in the patient after insertion and automatically recalibrate in vivo every two hours or sooner if patient or environmental conditions change.